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Abstract
The potency of nucleotide antagonists at P2Y1 receptors was enhanced by replacing the ribose 
moiety with a constrained carbocyclic ring (Nandanan, et al. J. Med. Chem. 2000, 43, 829—842). 
We have now synthesized ring-constrained methanocarba analogues (in which a fused 
cyclopropane moiety constrains the pseudosugar ring) of adenine and uracil nucleotides, the 
endogenous activators of P2Y receptors. Methanocarba-adenosine 5′-triphosphate (ATP) was fixed 
in either a Northern (N) or a Southern (S) conformation, as defined in the pseudorotational cycle. 
(N)-Methanocarba-uridine was prepared from the 1-amino-pseudosugar ring by treatment with β-
ethoxyacryloyl cyanate and cyclization to form the uracil ring. Phosphorylation was carried out at 
the 5′-hydroxyl group through a multistep process: Reaction with phosphoramidite followed by 
oxidation provided the 5′-monophosphates, which then were treated with 1,1′-carbonyldiimidazole 
for condensation with additional phosphate groups. The ability of the analogues to stimulate 
phospholipase C through activation of turkey P2Y1 or human P2Y1, P2Y2, P2Y4, P2Y6, and 
P2Y11 receptors stably expressed in astrocytoma cells was measured. At recombinant human P2Y1 
and P2Y2 receptors, (N)-methanocarba-ATP was 138- and 41-fold, respectively, more potent than 
racemic (S)-methanocarba-ATP as an agonist. (N)-methanocarba-ATP activated P2Y11 receptors 
with a potency similar to ATP. (N)-Methanocarba-uridine 5′-triphosphate (UTP) was equipotent to 
UTP as an agonist at human P2Y2 receptors and also activated P2Y4 receptors with an EC50 of 85 
nM. (N)-Methanocarba-uridine 5′-diphosphate (UDP) was inactive at the hP2Y6 receptor. The 
vascular effects of (N)-methanocarba-UTP and (N)-methanocarba-UDP were studied in a model of 
the rat mesenteric artery. The triphosphate was more potent than UTP in inducing a dilatory P2Y4 
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response (pEC50 = 6.1 ± 0.2), while the diphosphate was inactive as either an agonist or antagonist 
in a P2Y6 receptor-mediated contractile response. Our results suggest that new nucleotide agonists 
may be designed on the basis of the (N) conformation that favors selectivity for P2Y1, P2Y2, 
P2Y4, and P2Y11 receptors.
 Introduction
P2 receptors, which are activated by purine and/or pyrimidine nucleotides, consist of two 
families: G protein-coupled receptors termed P2Y, of which six mammalian subtypes have 
been cloned, and ligand-gated cation channels termed P2X, of which seven mammalian 
subtypes have been cloned.1–3 The nomenclature of P2 receptors and their various ligand 
specificities has been reviewed.4–7 Uracil nucleotides activate P2Y2, P2Y4, and P2Y6 
subtypes. Adenine nucleotides are required for the activation of P2Y1 and P2Y11 subtypes. 
Activation of P2Y receptors generally results in the stimulation of phospholipase C (PLC), 
which generates inositol phosphates and diacylglycerol from phosphatidyl 
inositol(4,5)bisphosphate,8 leading to a rise in intracellular calcium and activation of protein 
kinase C. The P2Y11 receptor activates adenylyl cyclase in addition to the activation of 
PLC,9 and G protein-coupled P2Y receptors in C6 glioma cells10 and the recently cloned 
P2Y12 receptor in platelets11 inhibit adenylyl cyclase.
The P2Y1 receptor is present in the heart, skeletal, and various smooth muscles, prostate, 
ovary, and brain.12 A selective P2Y1 receptor agonist may have potential as an 
antihypertensive or antidiabetic agent.13,14 The P2Y2 receptor is associated with the ion 
secretory actions of uridine 5′-triphosphate (UTP) and adenosine 5′-triphosphate (ATP) in 
the mucosa of the nasal and tracheal epithelia and is a target in therapeutics of pulmonary 
diseases, e.g., cystic fibrosis15,16 and ophthalmic diseases.17 The P2Y4 and P2Y6 receptors 
may have a role in regulation of blood flow18 and have been implicated in the 
gastrointestinal responses to UTP and uridine 5′-diphosphate (UDP).16 The P2Y11 receptor 
subtype is present in the immune system, and the P2Y12 receptor subtype plays a key role in 
ADP action in platelets. Currently, there are few selective agonists or antagonists at these 
subtypes.7 While numerous adenine nucleotide ligands have been explored at the P2Y1 
receptor, few uracil nucleotides have been reported as P2Y receptor agonists.15,18
Conformational considerations of both the receptors and their ligands are important in 
structure-based drug design. The ribose rings of purine and pyrimidine nucleotides can adopt 
a range of conformations, although the P2 receptors, which they activate, likely prefer 
specific conformations. Therefore, constraining the riboselike ring of nucleotide analogues 
would help establish these parameters, and we hypothesize that an analogue in which the 
ribose has been replaced with a carbocyclic ring locked in a preferred conformation may 
display unique potency and selectivity. Thus, we have adopted the methanocarba 
approach,19 in which fused cyclopropane and cyclopentane rings replace the ribose moiety. 
Two structural variations, depending on the position of the cyclopropane ring, restrict the 
ring pucker, i.e., hold the riboselike ring (pseudosugar) in either a Northern (N, 2′-exo) or a 
Southern (S, 2′-endo) envelope conformation, as defined in the pseudorotational cycle. For 
two classes of purine ligands, i.e., adenosine bisphosphate derivatives binding at P2Y1 
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receptors20 and adenosine derivatives binding at A1 and A3 receptors,21 a preference for the 
(N)-methanocarba isomer already has been demonstrated. At P2Y1 receptors, the ribose-
containing antagonist 2-chloro-2′-deoxy-N6-methyladenosine-3′,5′-bisphosphate, 1, has 
been substituted with the (N)-methanocarba modification to yield (1R,2S,4S,5S)-1-
[(phosphato)methyl]-4-(2-chloro-6-methylaminopurin-9-yl)bicyclo[3.1.0]hexane-2-
phosphate, 2.20 Both 1 and 2 are selective antagonists of the turkey erythrocyte P2Y1 
receptor, with 2 (IC50 52 nM) approximately 4-fold more potent than 1.
We wished to determine if the preference for the (N) conformation applies to subtypes other 
than P2Y1 receptors and also whether this preference seen for bisphosphate antagonist 
derivatives is generalizable to 5′-triphosphate agonists and to pyrimidine as well as purine 
nucleotides. Here, we describe the synthesis and biological characterization in several 
species of the methanocarba analogues of adenine and uracil nucleotides. For direct 
comparison, the adenine nucleotide analogues have been locked in both the (N) ring and the 
(S) ring conformations. In general, the constrained (N) conformation of the pseudoribose 
ring increased agonist potencies at P2Y1 receptors and preserved potencies at P2Y2, P2Y4, 
and P2Y11 receptors but not at the UDP-activated P2Y6 receptor. The corresponding (S) 




Methanocarbocyclic analogues of naturally occuring adenine and uracil nucleotides (Table 
1) were synthesized containing fused cyclopropane and cyclopentane rings that fixed the 
pseudoribose moiety in a rigid (N) or (S) envelope conformation. Nucleotide analogues 
having either the (N)-methanocarba modification,19,20 3a–7a, or the (S)-methanocarba 
modification,22 8a and 9a, were prepared in the ammonium salt form according to the 
methods shown in Schemes 1–4 and tested biologically as agonists at various P2Y receptors 
(Table 1). Identity was confirmed using nuclear magnetic resonance (NMR, 1H and 31P) and 
high-resolution mass spectrometry, and purity was demonstrated using high-pressure liquid 
chromatography (HPLC) in two different solvent systems (Table 2).
Several methods of 5′-phosphorylation of the (N)-methanocarba nucleoside were compared. 
A standard method using sequential reaction with phosphorus oxychloride and 
pyrophosphate to provide nucleoside 5′-triphosphate analogues23 proved problematic. 
Several attempts to obtain the (N)-methanocarba-UTP by variations of this one-pot method 
were unsuccessful. We have evidence that the one-pot method in the (N) series leads to the 
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formation of cyclic-3′,5′-nucleotides (unpublished, V. Marquez). This is due to the close 
proximity between the 3′-OH and the 5′-OH that can be achieved only in the fixed (N) 
envelope conformation. On the other hand, these two hydroxyl groups never come close to 
one another in the antipodal (S) conformers. Therefore, the multistep elongation of a 5′-
monophosphate group to di-and triphosphates was pursued. The general method adopted 
(Scheme 1) consisted of reaction of 1,1′-carbonyldiimidazole24,25 with a nucleoside 5′-
monophosphate, I, followed by the addition of either phosphate or pyrophosphate. By this 
method, the monophosphate analogues were cleanly converted to either di- or triphosphate, 
III or IV, respectively, via a phosphorimidazolidate intermediate, II. Typically, the 
monophosphate, I, was treated with an excess of carbonyldiimidazole in N,N-
dimethylformamide (DMF) and stirred for 4–6 h. To hydrolyze the cyclic carbonate24 that 
formed at the 2′,3′-dihydroxy groups, a 5% triethylamine solution in MeOH:water (1/1) was 
added to the reaction mixture, and stirring was continued for 2 h. HPLC monitoring of this 
reaction step indicated that the phosphorimidazolidate, II, was stable to mild base treatment. 
This intermediate, II, was treated with phosphoric acid tributylammonium salt or with 
pyrophosphoric acid tributylammonium salt to give the diphosphate, III, or triphosphate, IV, 
respectively.
The (N)-methanocarba analogues of ATP and adenosine 5′-monophosphate (AMP) were 
prepared by this approach (Scheme 2). The (N)-methanocarba-adenosine precursors were 
prepared by the general approaches of Marquez and co-workers19,26,27 or Lee et al.28 6-
Chloropurine, 10, was condensed with the protected bicyclo- [3.1.0]hexane derivative, 11,28 
using Mitsunobu conditions to give 12, which was then treated with a saturated solution of 
ammonia in THF to give the corresponding adenosine analogue, 13. Deprotection of a 5′-
benzyl group of 13 was carried out smoothly using Pd black/formic acid to give 14 and was 
followed by phosphorylation using a phosphoramidite method29 to give the di-tert-butyl-
protected monophosphate, 15. The monophosphate, 15, was deprotected and either tested 
biologically or carried further to the di- and triphosphates by the method shown in Scheme 
1.
The (N)-methanocarba analogues of UTP (5a), UDP (6a), and UMP (7a), were also 
prepared. A synthetic route to (N)-methanocarba-uridine as a precursor for uracil nucleotide 
analogues was devised (Scheme 3). Several attempts to condense uracil and the pseudosugar 
moiety by the Mitsunobu reaction gave only a di-O-alkylated byproduct, likely due to the 
low solubility of uracil in tetrahydrofuran (THF). A protected uracil derivative having 
greater solubility in THF, 3-benzoyluracil,30 was used as a reactant in the Mitsunobu 
reaction; however, an O-alkylated byproduct resulted. Eventually, formation of the uracil 
moiety was achieved in two sequential steps (Scheme 3).31 The aminocyclopentane 
derivative, 16, was converted to an acryloylureido compound (isolated but not shown in 
Scheme 3) by treatment with β-ethoxyacryloyl cyanate.31 Cyclization upon refluxing in 2 N 
sulfuric acid and methanol gave the 5′-protected (N)-methanocarbauracil, 17, in good yield. 
Removal of the O-benzyl group with palladium black and formic acid in methanol afforded 
the triol, 18. The acetonide of the 2,3-diol, 19, was prepared, and the primary alcohol was 
converted to the di-tert-butyl phosphate, 20.29 Both di-tert-butyl and acetonide groups were 
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deprotected simultaneously under acidic conditions, leading to the successful synthesis of 
monophosphate, 7a.
The (S)-methanocarba analogues of ATP and AMP, 8a and 9a (Scheme 4), respectively, 
were prepared using a sequential phosphorus oxychloride method from the unprotected, 
racemic (S)-methanocarba-adenosine, 21.22 The monophosphate, 9a, was isolated and 
converted to the triphosphate, 8a, using carbonyldiimidazole.
 Biological Activity
Methanocarba analogues were tested for agonist activity by measuring P2Y1 receptor-
promoted PLC activity in turkey erythrocyte membranes and by measuring inositol 
phosphate accumulation in 1321N1 human astrocytoma cells stably expressing the human 
P2Y1, P2Y2, P2Y4, P2Y6, or P2Y11 receptors. In each case, full concentration effect curves 
were generated, and EC50 values from at least three separate experiments were determined 
(Table 1). The agonist potencies of the corresponding ribose-containing nucleotides (denoted 
“b”) were simultaneously determined for comparison purposes.
The (N)-methanocarba-ATP analogue, 3a, was 250-fold more potent than the racemic (S)-
methanocarba-ATP analogue, 8a, and 200-fold more potent than ATP, 3b, at the turkey P2Y1 
receptor (Table 1). The (N)-methanocarba-ATP analogue, 3a, was also more potent than the 
corresponding (S)-methanocarba analogue, 8a, at the recombinant human P2Y1 and P2Y2 
receptors, by factors of 138- and 41-fold, respectively (Figure 1 and Table 1). The (N) and 
(S) isomers of methanocarba-ATP were full agonists at both the P2Y1 and the P2Y2 
receptors. At the human P2Y1 receptor (N)-methanocarba-ATP, 3a, displaying an EC50 
value of 52 nM, was 29-fold more potent than ATP, 3b. In contrast, the (N)-methanocarba-
ATP analogue was equipotent with ATP at the human P2Y2 receptor and also exhibited a 
similar potency to ATP at the P2Y11 receptor. Note that concentration-effect curves for 3a at 
the human P2Y11 receptor were only carried out to 10 µM concentration. Nonetheless, these 
curves predicted an EC50 for 3a essentially equivalent to that of ATP (~20 µM). As is the 
case with ATP, (N)-methanocarba-ATP was not an agonist at the human P2Y4 receptor. The 
(N)-methanocarba-AMP analogue, 4a, was not active at the turkey P2Y1 receptor.
(N)-Methanocarba analogues of uridine nucleotides also were synthesized as potential 
agonists at the uracil-activated, P2Y2, or uracil selective, P2Y4 and P2Y6, receptors. The 
high potency in the (N)-methanocarba series was maintained or increased at the human 
P2Y2 and P2Y4 receptor subtypes, where the (N)-methanocarba-UTP analogue, 5a, was 
only slightly less potent than UTP (Table 1 and Figure 2). Like UTP, the (N)-methanocarba-
UTP analogue was inactive at the human P2Y6 and P2Y11 receptors. Surprisingly, the (N)-
methanocarba-UDP analogue, 6a, was inactive at the UDP-selective human P2Y6 receptor 
(Figure 3). (N)-Methanocarba-UMP also was without effect at the P2Y6 receptor.
The vascular effects of (N)-methanocarba-UTP, 5a, and (N)-methanocarba-UDP, 6a, were 
studied in a model of the rat mesenteric artery, in which uracil nucleotides elicit both 
dilatory and contractile responses (Figures 4–6).18 The dilatory response is dependent on the 
activation of endothelial P2Y2,4 receptors by UTP, and the contractile response is mainly 
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dependent on activation of vascular smooth muscle P2Y6 receptors by UDP with a small 
P2Y2,4 receptor-dependent component.
Compound 5a was significantly more potent than UTP in inducing a dilatory response 
(pEC50 ) 6.1 ± 0.2 for 5a and 5.5 ± 0.2 for 5b, Figure 4). The maximal dilatory effects 
(Rmax, as a percentage of the corresponding precontraction with 1 µM norepinephrine) 
observed were 70.6 ± 9.5 and 50.0 ± 14.7% for 5a and 5b, respectively. In the contractile 
response (Figure 5), although a response could be observed for UDP, (N)-methanocarba-
UDP, 6a, had no agonist effect at a concentration of 300 µM. Compound 5a induced 
contractions but much more weakly than the ribose equivalent, UTP. Contraction induced at 
an agonist concentration of 100 µM, expressed as percent of the response to 60 mM 
potassium, was 17.2 ± 6.6% (n = 4) for 5a and 52.6 ± 18.6% (n = 5) for 5b. A complete 
dose-response curve could not be constructed for 5a, due to limited amounts of the 
compound. These results are consistent with selectivities observed at the human P2Y 
receptors, in which the (N)-methanocarba modification precluded activation of P2Y6 
receptors.
Because (N)-methanocarba-UDP, 6a, did not have any agonistic (contractile) effects on the 
P2Y6 receptors in this preparation, we wanted to examine a possible antagonistic effect. (N)-
Methanocarba-UDP, 6a, was demonstrated to lack any antagonistic effects at the UDP-
mediated contraction. In this preparation, UDP at 100 µM produced a 33.9 ±7.1% 
contraction (n = 4) in the absence of 6a and a 34.0 ±2.4% contraction (n = 4) following 
pretreatment with 6a (Figure 6).
 Discussion
Our previous work with bisphosphate adenosine derivatives as P2Y1 receptor antagonists 
revealed that high binding affinity at the P2Y1 receptor was retained in nonnucleotide 
bisphosphate analogues.20 Indeed, replacement of the ribose moiety with a constrained 
carbocyclic ring, e.g., 2, enhanced P2Y1 receptor affinity. Here, we have synthesized ring-
constrained methanocarba analogues of ATP and UTP and illustrated that these derivatives 
exhibit as high or even higher potency for activation of certain P2Y receptors than the 
corresponding natural nucleotide. As was observed with bisphosphate antagonists of the 
P2Y1 receptor, the presence of a fused cyclopropane moiety constraining a cyclopentane in a 
pseudorotational (N) conformation produced an agonist at adenine and uridine nucleotide 
activated P2Y receptors that was much more potent than the corresponding molecule 
constrained in the (S) conformation.
The methanocarba modification, originally applied by Marquez and co-workers to antiviral 
nucleosides, fixes the ring pucker conformation in carbocyclic analogues by virtue of a 
bridging cyclopropane ring.26,27,31 The (N) conformation of the pseudorotational cycle was 
clearly favored in binding of the methanocarba-ATP analogue in the turkey and human P2Y1 
receptors and the hP2Y2 receptor. The difference in fit in the binding pocket observed with 
the (N) and (S) conformers of ATP was ~300-fold at the P2Y1 receptor (turkey) and 41-fold 
at the hP2Y2 receptor. The potency enhancement in (N) methanocarba-ATP vs its ribose 
equivalent was 350-fold at the P2Y1 receptor (turkey) and was insignificant at the hP2Y2 
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receptor. In another study (in preparation), we have extended this finding of preference for 
the (N) conformers at the P2Y1 receptor to molecules that also possess other functional 
groups, e.g., 2-MeS or N6-CH3 substitution, known to increase binding affinity and 
selectivity for P2Y receptor agonists.
The observation that the (N)-methanocarba analogue of UDP was inactive at the UDP-
activated hP2Y6 receptor was very surprising given the activity of (N) methanocarba 
analogues at the P2Y1 and P2Y2 receptors and the fact that (N)-methanocarba-UTP was 
essentially equipotent with UTP at the hP2Y4 receptor. Therefore, the binding pocket of the 
P2Y6 receptor must markedly differ from that of at least three of its family members. As 
such, it will be important to extend analyses of activities of potential agonists in the (N) vs 
(S) conformations to studies of all members of the human P2Y receptor family.
The relative activities observed with the methanocarba analogues of UTP and UDP 
apparently are retained at rat uracil nucleotide-activated P2Y receptors. (N)-Methanocarba-
UTP, 5a, was more potent than UTP as a vasodilator in the rat mesenteric artery containing 
intact endothelium, which may be due to greater resistance of (N)-methanocarba-UTP, 5a, to 
ectonucleotidase activity or to higher P2Y2,4 receptor potency. However, (N)-methanocarba-
UTP, 5a, was less potent than UTP for inducing vascular contraction in endothelium-
denuded rat mesenteric artery, and (N) methanocarba-UDP, 6a, did not exhibit any 
contractile effect involving both P2Y2,4 and P2Y6 receptor-mediated components.18 A likely 
explanation for the inactivity of (N)-methanocarba-UDP, 6a, is that it does not possess any 
agonist activity at the rat P2Y6 receptor.
In previous experiments,18 we found that the stable UDP analogue, β-thio-UDP, was more 
potent in the contractile response than a stable UTP analogue, although the reverse was true 
for the natural pyrimidines (UTP was more potent than UDP). Our interpretation was that 
the P2Y6 receptor is a more important vasoconstrictor than P2Y2,4 and that UTP mediates its 
contraction mainly after degradation to UDP.
In the present study, (N)-methanocarba-UTP, 5a, may be degraded to (N)-methanocarba-
UDP, 6a, although it may be more stable than UTP due to the methanocarba substitution. 
The lack of contractile effect of (N) methanocarba-UDP, 6a, can explain the low potency for 
(N)-methanocarba-UTP, 5a, as a vasoconstrictor, as compared to its activity as a vasodilator 
through P2Y2,4 receptors. Differences in the expression of P2Y2 and P2Y4 receptors at 
endothelium vs smooth muscle could also contribute to this phenomenon.
Thus, it appears that (N)-methanocarba-UDP, 6a, was neither an agonist nor an antagonist at 
the rat P2Y6 receptor, and the weak contractile effect of (N)-methanocarba-UTP, 5a, was 
from action at P2Y2,4 receptors alone. While UDP and its more stable analogue β-thio UDP 
can be used to define action at P2Y6 receptors,18 it will be useful to have a molecule such as 
(N) methanocarba-UTP, 5a, that exhibits the opposite selectivity, i.e., active at P2Y2,4 
receptors but inactive, itself or through a metabolite, at P2Y6 receptors.
In conclusion, we have established that constraining the riboselike ring as methanocarba 
analogues is an important principle for producing P2Y receptor subtype selectivity, similar 
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to our previous demonstration of this phenomenon for P2Y1 receptor antagonists. These 
findings promise to be useful in both defining the microscopic determinants of the binding 
sites on these receptors and in the design of novel pharmacological probes and/or therapeutic 
agents. We observed that the (N) ring conformation was associated with increased agonist 
potency at P2Y1 receptors and preserved agonist potency at P2Y2, P2Y4, and P2Y11 but not 
P2Y6 receptors. This suggests that new, nucleotide agonists may be designed on the basis of 
the (N) conformation that favors P2Y receptor subtype selectivity.
 Experimental Section
 Chemical Synthesis
Nucleosides and synthetic reagents were purchased from Sigma Chemical Co. (St. Louis, 
MO) and Aldrich (Milwaukee, WI). 2,6-Dichloropurine was obtained from Sigma. 
Compound 12 was synthesized in our laboratory as described.28,32
1H NMR spectra were obtained with a Varian Gemini-300 spectrometer (300 MHz) using 
D2O and CDCl3, CD3OD as a solvent. 31P NMR spectra were recorded at room temperature 
by use of a Varian XL-300 spectrometer (121.42 MHz); orthophosphoric acid (85%) was 
used as an external standard.
Purity of all compounds submitted to biological testing was checked using a Hewlett-
Packard 1090 HPLC apparatus equipped with a C18 reverse phase analytical column (250 × 
4.6 mm, as specified in Table 2) in two solvent systems. Peaks were detected by UV 
absorption using a diode array detector. All derivatives showed more than 95% purity in the 
HPLC systems.
Low-resolution CI-NH3 (chemical ionization) mass spectra were carried out with Finnigan 
4600 mass spectrometer and high-resolution EI (electron impact) mass spectrometry with a 
VG7070F mass spectrometer at 6 kV. High-resolution FAB (fast atom bombardment) mass 
spectrometry was performed with a JEOL SX102 spectrometer using 6 kV Xe atoms 
following desorption from a glycerol matrix. Purification of the nucleotide analogues for 
biological testing was carried out on (diethylamino)ethyl (DEAE)-A25 Sephadex columns as 
described above.
 General Phosphorylation Procedure. Synthesis of (N)-Methanocarba-adenosine 
Derivative (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-9H-purin-9-yl)-1-[(phenylmethoxy)methyl]-
bicyclo[3.1.0]hexane-2,3-(O-isopropylidine) (13)
To a solution of 12 (0.2 g, 0.47 mmol) in i-PrOH (3 mL) was added NH3 (2 M solution in 
iPrOH, 5 mL, 10 mmol), and the reaction mixture was heated at 90 °C in a closed tube for 
15 h for complete reaction. The resulting mixture was concentrated under reduced pressure, 
and the residue obtained was purified by flash chromatography using 9/1 CHCl3/MeOH to 
furnish 0.182 g of 13 (95%). 1H NMR (CDCl3): δ 8.35 (s, 1H), 8.30 (s, 1H), 7.37 (s, 5H), 
5.87 (bs, 2H), 5.31 (d, 1H, J = 6.8 Hz), 5.13 (s, 1H), 4.64 (qAB, 2H, J = 11.7, 20.5 Hz), 4.51 
(d, 1H, J = 6.8 Hz), 3.97 (d, 1H, J = 10.7 Hz), 3.35 (d, 1H, J = 10.7 Hz), 1.72–1.62 (m, 1H), 
1.55 (s, 3H), 1.32–1.26 (m, 1H), 1.23 (s, 3H), 1.00–0.93 (m, 1H).
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To a solution of 13 (0.182 g, 0.45 mmol) in 5% formic acid in MeOH (15 mL) at room 
temperature was added 0.15 g of palladium black and stirred at the same temperature for 24 
h. The resulting mixture was filtered through a plug of Celite and concentrated under 
reduced pressure. The crude product obtained was purified by flash chromatography using 
9/1 CHCl3/MeOH to furnish 0.12 g of 14 (76%).1H NMR (CDCl3): δ 8.35 (s, 1H), 7.83 (s, 
1H), 5.94 (bs, 2H), 5.61 (d, 1H, J = 7.2 Hz), 4.79 (s, 1H), 4.66 (d, 1H, J = 7.2 Hz), 4.31 (d, 
1H, J = 11.5 Hz), 3.26 (d, 1H, J = 11.5 Hz), 1.9–1.7 (m, 1H), 1.55 (s, 3H), 1.25 (s, 3H), 
1.22–1.10 (m, 1H), 1.10–0.94 (m, 1H).
 Synthesis of Protected (N)-Methanocarba-AMP Derivative. (1′S,2′R,3′S,4′R,5′S)-4-(6-
Amino-9H-purin-9-yl)-1-[(di-tert-butylphosphato)methyl]bicyclo[3.1.0]hexane-2,3-(O-
isopropylidine) (15)
To a stirred solution of di-tert-butyl diethylphosphoramidite and 14 (0.040 g, 0.138 mmol) in 
4 mL of anhydrous THF, tetrazole (0.029 g, 0.42 mmol) was added, and the mixture was 
stirred for 6 h at room temperature. The reaction mixture was cooled to −78 °C, and a 
solution of MCPBA (70% max, 0.04 g) in CH2Cl2 (2 mL) was added. The resulting mixture 
was warmed to room temperature, and the solvent was removed under reduced pressure. The 
residue obtained was purified by preparative thin-layer chromatography (9/1 CHCl3/MeOH), 
which furnished 0.055 g (78%) of the di-tert-phosphate ester 15. 1H NMR (CDCl3): δ 8.37 
(s, 1H), 8.19 (s, 1H), 6.46 (bs, 2H), 5.31 (d, 1H, J = 6.6 Hz), 5.12 (s, 1H), 4.6–4.42 (m, 2H), 
3.92–3.76 (m, 1H), 1.84–1.72 (m, 1H), 1.55 (s, 3H), 1.51 (s, 9H), 1.50 (s, 9H), 1.34–1.26 
(m, 1H), 1.23 (s, 3H), 1.12–1.00 (m, 1H).
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-9H-purin-9-yl)-1-
[phosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (4a)
Compound 15 (0.05 g, 0.097 mmol) was heated at 80 °C with DOWEX-50-80-200 resin 
(0.200 g) in 1/1 MeOH/H2O (10 mL) for 1.5 h. The resin was removed by filtration, and the 
filtrate was concentrated under reduced pressure. The residue was purified by a Sephadex 
column using 200 mL of H2O and 200 mL of 0.5 M NH4HCO3 solution, which furnished 
0.05 g of 4a as triethylammonium salt (69%). 1H NMR (D2O): δ 8.54 (s, 1H), 8.17 (s, 1H), 
4.31 (dd, 1H, J = 4.8, 11.3 Hz), 4.01 (d, 1H, J = 6.5 Hz), 3.62 (dd, 1H, J = 4.3, 11.3 Hz), 
1.86–1.80 (m, 1H), 1.52–1.44 (m, 1H), 1.00–0.92 (m, 1H). 31P NMR (D2O): δ 0.98.
 (±)-5-(6-Amino-9H-purin-9-yl)-1-[phosphoryloxymethyl]-bicyclo[3.1.0]hexane-2,3-diol (9a)
To a solution of compound 21 (0.015 g, 0.05 mmol) and Proton Sponge (0.053 g, 0.25 
mmol) in trimethyl phosphate was added POCl3 at 0 °C, and the mixture was stirred for 40 
min. Triethylammonium bicarbonate buffer (1.0 M, pH 8.5, 2 mL) was added to the reaction 
mixture followed by the addition of 2 mL of water. The reaction mixture was lyophilized, 
and the residue obtained was purified on a Sephadex column eluting with 0.5 M ammonium 
bicarbonate:water (100 mL:100 mL) to obtain 0.015 g (60%) of the monophosphate, 9a. 1H 
NMR (D2O): δ 8.33 (s, 1H), 8.23 (s, 1H), 4.16–4.08 (m, 3H), 3.57 (d, J = 10.44 Hz, 1H), 
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2.40–2.42 (m, 1H), 1.98–1.94 (m, 1H), 1.88–1.82 (m, 1H), 1.46–1.40 (m, 1H). 31P NMR 
(D2O): δ 0.80.
 Synthesis of Methanocarba ATP Analogues. (1′S,2′R,-3′S,4′R,5′S)-4-(6-Amino-9H–
purin-9-yl)-1-[triphosphoryl-oxymethyl]bicyclo[3.1.0]hexane-2,3-diol (3a)
A mixture of 4a (0.05 g, 0.089 mmol) and 1,1′carbonyldiimidazole (0.086 g, 0.534 mmol) in 
2 mL of anhydrous DMF was stirred at room temperature for 8 h. The reaction mixture was 
treated with 5% Et3N in MeOH and stirred for 2 h. Solvent was removed under reduced 
pressure, and the residue was dried in high vacuum. To this residue was added 
tributylammonium pyrophosphate (0.4 g, 0.89 mmol) suspended in 2 mL of anhydrous 
DMF. To this mixture was added 0.1 mL of tributylamine and stirred at room temperature 
for 3 days. Triethylammonium bicarbonate (3 mL) was added, and the solvent was removed. 
The residue obtained was purified by a Sephadex column using 200 mL of H2O and 200 mL 
of 0.5 M NH4HCO3 solution, which furnished 0.010 g of triphosphate 3a (20%). 1H NMR 
(D2O): δ 8.50 (s, 1H), 4.73 (s, 1H), 4.58 (dd, 1H, J = 4.7, 11.0 Hz), 4.02 (d, 1H, J = 6.6 Hz), 
3.87 (dd, 1H, J =4.7, 11.0 Hz), 1.96–1.91 (m, 1H), 1.58–1.52 (m, 1H), 1.06–0.98 (m, 
1H). 31P NMR (D2O): δ d (−10.27, −10.43), d (−10.67, −10.84), bs −22.61.
 (±)-5-(6-Amino-9H-purin-9-yl)-1-[triphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol 
(8a)
Synthesis of 8a from 9a (0.007 g, 0.02 mmol), 1,1′carbonyldiimidazole (0.016 g, 0.1 mmol) 
and tributylammonium pyrophosphate (0.055 g, 0.12 mmol), was carried out by the same 
general procedure as for 3a to furnish 0.003 mg (30%). 1H NMR (D2O): δ 8.33 (s, 1H), 8.23 
(s, 1H), 4.42–4.02 (m, 3H), 3.20 (d, J = 7.41 Hz, 1H), 2.50–2.64 (m, 1H), 2.02 – 1.75 (m, 
1H), 1.58–1.35 (m, 1H), 1.30–1.22 (m, 1H). 31P NMR (D2O): δ −5.70, −10.47, −21.16.
 (1′S,2′R,3′S,4′R,5′S)-4-(2,4(H,3H)-Dioxopyrimidin-1-yl)-1-
[(phenylmethoxy)methyl]bicyclo[3.1.0]hexane-2,3-diol (17)
A solution of β-ethoxyacryloyl cyanate (0.7 mmol) in anhydrous benzene (2 mL) was added 
rapidly to a stirred solution of amine 16 (105 mg, 0.363 mmol) in anhydrous benzene (1 mL) 
at room temperature. The reaction mixture was stirred at the same temperature for 10 min, 
diluted with ethyl acetate (30 mL), and treated with saturated aqueous sodium bicarbonate 
(10 mL). After the solution was stirred for 20 min at room temperature, the organic layer 
was separated, washed with brine (10 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo. The residue was purified by flash chromatography using 1/2 hexane/ethyl acetate to 
furnish 126 mg of an intermediate (89%) as a syrup. 1H NMR (CDCl3): δ 8.97 (s, 1H), 8.89 
(d, 1H, J = 7.2 Hz), 7.64 (d, 1H, J = 12.2 Hz), 7.20–7.41 (m, 5H), 5.30 (d, 1H, J = 12.2 Hz), 
5.05 (dd, 1H, J = 1.0, 7.2 Hz), 4.58 (s, 2H), 4.55 (dd, 1H, J = 1.0, 7.3 Hz), 4.19 (d, 1H, J = 
7.3 Hz), 3.97 (q, 2H, J = 7.1 Hz), 3.63 (d, 1H, J = 10.4 Hz), 3.40 (d, 1H, J = 10.4 Hz), 1.49 
(s, 3H), 1.45 (dddd, 1H, J = 1.2, 5.5, 8.0 Hz), 1.35 (t, 3H, J = 7.1 Hz), 1.24 (s, 3H), 1.05 (t, 
1H, J = 5.1 Hz), 0.78 (ddd, 1H, J = 1.2, 5.5, 9.2 Hz).
The acryloylureidohexane (130 mg, 0.302 mmol) was refluxed in 2 N H2SO4 (8 mL). After 
it was refluxed for 30 min, methanol (5 mL) was added to completely dissolve the substrate 
and form a homogeneous solution. After the solution was stirred for 10 min at reflux 
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temperature, the methanol was removed by purging with an N2 stream with heating at 
120 °C. The residue (a clear aqueous solution) was refluxed for an additional 30 min. The 
resulting mixture was cooled to room temperature and neutralized with solid sodium 
bicarbonate until no further gas evolution was detected. The mixture was lyophilized, and 
the residue was extracted with a mixed solvent (chloroform/methanol = 1:1, 20 mL × 3) and 
filtered through a plug of silica gel to remove all inorganic salts. The filtrate was 
concentrated in vacuo and purified by flash chromatography using 6/1 CHCl3/MeOH to 
furnish 70 mg of 17 (67.3%) as a syrup. 1H NMR (CD3OD): δ 8.18 (d, 1H, J = 8.1 Hz), 
7.28–7.45 (m, 5H), 5.22 (d, 1H, J = 8.1 Hz), 4.77 (s, 1H), 4.60 (d, 1H, J = 11.1 Hz), 4.59 
(dd, 1H, J = 1.5, 6.9 Hz), 4.53 (d, 1H, J = 11.1 Hz), 4.22 (d, 1H, J = 10.2 Hz), 3.73 (dd, 1H, 
J = 1.4, 6.9 Hz), 3.21 (d, 1H, J = 10.0 Hz), 1.49 (dd, 1H, J = 4.0, 5.2 Hz), 1.37 (ddd, 1H, J = 
1.6, 4.0, 8.8 Hz), 0.73 (ddd, 1H, J = 1.8, 5.5, 8.8 Hz). MS (m/e): 344 (M+). CIMS 
(ammonia) m/e: 345 (M+ + 1).
 (1′S,2′R,3′S,4′R,5′S)-4-(2,4(H,3H)-Dioxopyrimidin-1-yl)-1-
(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol (18)
Solid palladium black (60 mg) was added to a stirred solution of (1′S,2′R,3′S,4′R,5′S)-4-
(2,4(H,3H)-dioxopyrimidin-1-yl)-1-[(phenylmethoxy)methyl]bicyclo[3.1.0]hexane-2,3-diol 
(17, 23 mg, 0.0668 mmol) in methanol (4 mL), and 95% formic acid (1.3 mL) was added. 
The mixture was stirred at 50 °C for 4 h, additional formic acid (1.2 mL) was added, and 
stirring was continued at 60 °C for 3 h. The resulting mixture was cooled to room 
temperature, filtered through a plug of Celite, and washed with methanol. The filtrate was 
evaporated, and the product was purified by silica gel column chromatography (chloroform/
methanol = 2:1) to give 18 (12.6 mg, 74%) as a syrup. 1H NMR (CD3OD): δ 8.04 (d, 1H, J = 
8.0 Hz), 5.66 (d, 1H, J = 8.0 Hz), 4.72 (s, 1H), 4.58 (dd, 1H, J = 1.4, 6.9 Hz), 4.20 (d, 1H, J 
= 11.8 Hz), 3.81 (d, 1H, J = 6.9 Hz), 3.24 (d, 1H, J = 11.8 Hz), 1.30–1.41 (m, 2H), 0.68 
(ddd, 1H, J = 1.7, 4.4, 8.0 Hz). CIMS (ammonia) m/e: 255 (M+ + 1), 272 (M+ + NH4).
 (1′S,2′R,3′S,4′R,5′S)-4-(2,4(H,3H)-Dioxopyrimidin-1-yl)-1-
(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-(O-iso-propylidene) (19)
A mixture of triol 18 (20 mg, 0.0787 mmol) and p-toluene sulfonic acid monohydrate (50 
mg, 0.263 mmol) and acetone (7 mL) was stirred at ambient temperature for 4 h. 
Triethylamine (0.5 mL) was added to protect the acetonide group. All volatile materials were 
removed in vacuo, and the residue was purified by preparative thin-layer chromatography 
using 4/1 chloroform/methanol to give 20 mg of 19 as an oil (86%). 1H NMR (CDCl3): δ 
7.39 (d, 1H, J = 8.0 Hz), 5.74 (d, 1H, J = 8.0 Hz), 5.32 (dd, 1H, J ) 1.0, 7.3 Hz), 4.75 (d, 1H, 
J = 7.3 Hz), 4.31 (s, 1H), 4.18 (d, 1H, J = 11.4 Hz), 3.31 (d, 1H, J = 11.4 Hz), 1.53 (m, 1H), 
1.51 (s, 3H), 1.27 (s, 3H), 1.04 (dd, 1H, J = 4.7, 5.8 Hz), 0.91 (ddd, 1H, J = 1.2, 5.8, 9.2 Hz). 
CIMS (ammonia) m/e: 295 (M+ + 1), 312 (M+ + NH4).
 (1′S,2′R,3′S,4′R,5′S)-4-(2,4(H,3H)-Dioxopyrimidin-1-yl)-1-[(di-tert-
butylphosphato)methyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (20)
Neat di-tert-butyl N,N-diethylphosphoramidite (57 µL, 0.205 mmol) was added by syringe 
to a stirred solution of 19 (20 mg, 0.0680 mmol) in anhydrous THF (1 mL) at room 
Kim et al. Page 11













temperature, followed by an addition of solid tetrazole (43 mg, 0.614 mmol). After the 
solution was stirred at room temperature for 20 min, the reaction mixture was cooled to 
−78 °C, and a solution of MCPBA (57 ~ 85%, 58 mg) in methylene chloride (2 mL) was 
added rapidly. The reaction mixture was warmed to 0 °C and stirred for 5 min. 
Triethylamine (0.5 mL, 3.59 mmol) was added to maintain a basic condition in order to 
avoid cleavage of tert-butyl groups. Purification was accomplished using preparative thin-
layer chromatography 6/1 chloroform/methanol to give 26 mg of 20 (79%) as an oil. 1H 
NMR (CDCl3): δ 8.04 (d, 1H, J = 8.0 Hz), 5.77 (d, 1H, J = 8.0 Hz), 5.15 (d, 1H, J = 7.3 Hz), 
4.95 (s, 1H), 4.46–4.58 (m, 2H), 3.66 (dd, 1H, J = 6.7, 11.4 Hz), 1.54 (m, 1H), 1.51 (s, 3H), 
1.49 (s, 9H), 1.25 (s, 3H), 0.95 (m, 1H). CIMS (ammonia) m/e: 487 (M+ + 1).
 (1′S,2′R,3′S,4′R,5′S)-4-(2,4(H,3H)-Dioxopyrimidin-1-yl)-1-
(phosphoryloxymethyl)bicyclo[3.1.0]hexane-2,3-diol, Triethylammonium Salt (7a)
A mixture of 20 (13 mg, 0.0267 mmol) and DOWEX 50 × 8–200 ion-exchange resin (300 
mg) and methanol (4 mL)/water (2 mL) was stirred at 70–80 °C for 12 h. The resulting 
mixture was filtered and washed with water (~5 mL). The filtrate was lyophilized with 0.1 
M triethylammonium bicarbonate to give 10 mg of a triethylammonium salt, 7a (86%), as a 
white solid. As a triethylammonium salt: 1H NMR (D2O): δ 8.04 (d, 1H, J = 6.0 Hz), 5.93 
(d, 1H, J = 6.0 Hz), 4.75 (s, 1H), 4.68 (m, 1H), 4.38 (m, 1H), 3.98 (d, 1H, J = 4.7 Hz), 3.62 
(m, 1H), 3.20 (q, 2H, J = 7.3 Hz), 1.58 (m, 1H), 1.37 (m, 1H), 1.28 (t, 3H, J = 7.3 Hz), 0.92 
(m, 1H). CIMS (ammonia) m/e: 487 (M+ + 1), 272 (M+ + NH4). As a free acid: 1H NMR 
(D2O): δ 8.04 (d, 1H, J = 8.0 Hz), 5.92 (d, 1H, J = 8.0 Hz), 4.75 (s, 1H), 4.66 (d, 1H, J = 6.8 
Hz), 4.42 (m, 1H), 3.98 (d, 1H, J = 6.5 Hz), 3.62 (m, 1H), 1.60 (m, 1H), 1.38 (m, 1H), 0.92 
(m, 1H). High-resolution MS (negative-ion FAB) calcd for C11H14N2O8P [M2− + H+]−, 
333.0488; found, 333.0506. HPLC: 3.235 min (99%) in solvent system A, 3.466 min (98%) 
in system C.
 (1′S,2′R,3′S,4′R,5′S)-4-(2,4(H,3H)-Dioxopyrimidin-1-yl)-1-
(diphosphoryloxymethyl)bicyclo[3.1.0]hexane-2,3-di-ol, Ammonium Salt (6a)
Solid 1,1′-carbonyldiimidazole (6.9 mg, 42.5 µmol) was added to a stirred solution of 7a 
(3.0 mg, 6.89 µmol) in anhydrous DMF (0.5 mL) at room temperature. After the solution 
was stirred at room tempreature for 6 h, the reaction mixture was treated with 5% 
triethylamine solution (2.5 mL, in 1/1 water/methanol) and stirred for 2 h. All volatile 
materials were removed by purging with nitrogen stream, and the residue dried in vacuo at 
room temperature and dissolved in anhydrous DMF (0.5 mL). To this solution was 
successively added tributylamine (30 µL, 126 µmol) and a solution of 
bis(tributylammonium) salt of phosphoric acid (0.1 mL, in DMF). This salt was prepared by 
mixing tributylamine (128 mg, 0.69 mmol) and phosphoric acid (33.8 mg, 0.345 mmol) in 
DMF (1 mL). After this solution was stirred at room temperature for 2 days, 0.2 M 
triethylammonium bicarbonate (0.2 mL) was added, and the resulting mixture was 
lyophilized. The residue was purified by ion-exchange column chromatography using a 
Sephadex-DEAE A-25 resin with a linear gradient (0.01–1.0 M) of 1.0 M ammonium 
bicarbonate as the mobile phase to give 1.3 mg of 6a (40.5%) as a white solid. 1H NMR 
(D2O): δ 8.03 (d, 1H, J = 8.0 Hz), 5.96 (d, 1H, J = 8.0 Hz), 4.52 (m, 1H), 4.69–4.91(m, 2H), 
3.99 (d, 1H, J = 6.8 Hz), 3.77 (m, 1H), 1.64 (m, 1H), 1.39 (m, 1H), 0.95 (t, 1H, J = 7.2 
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Hz). 31P NMR (D2O): δ −10.81, 9.98. MS (negative-ion FAB): 414 [M2− + H+]−. High-
resolution MS (negative-ion FAB) calcd for C11H15N2O11P2 [M2− + H+]−, 413.0151; found, 
413.0143. HPLC: 2.130 min (98%) in solvent system A, 4.531 (97%) min in system C.
 (1′S,2′R,3′S,4′R,5′S)-4-(2,4(H,3H)-Dioxopyrimidin-1-yl)-1-
(triphosphorylphosphoryloxymethyl)bicyclo[3.1.0]-hexane-2,3-diol, Triethylamine Salt (5a)
Solid carbonyl diimidazole (26 mg, 0.16 mmol) was added to a stirred solution of 7a and 
free acid (9.0 mg, 26.9 µmol) in anhydrous DMF (0.5 mL) at room temperature. After the 
solution was stirred at room temperature for 6 h, the reaction mixture was treated with 5% 
triethylamine solution (2.5 mL, in water/methanol = 1:1) and stirred for 2 h. All volatile 
materials were removed by purging with nitrogen, and the residue was dried in vacuo at 
room temperature. The product was purified by ion-exchange column chromatography using 
a Sephadex-DEAE A-25 resin with a linear gradient (0.01–0.5 M) of 0.5 M 
triethylammonium bicarbonate as the mobile phase, to give 15 mg of the 
phosphorimidazolidate monotriethylamine salt, as a white solid. 1H NMR (D2O): δ 7.96 (bs, 
1H), 7.81 (d, 1H, J = 7.9 Hz), 7.33 (bs, 1H), 7.15 (bs, 1H), 5.85 (d, 1H, J = 7.9 Hz), 4.70 (s, 
1H), 4.51 (d, 1H, J = 6.3 Hz), 4.38 (dd, 1H, J = 5.7, 11.3 Hz), 3.94 (d, 1H, J = 6.7 Hz), 3.61 
(dd, 1H, J = 5.3, 11.3 Hz), 3.02–3.38 (m, 6H), 1.47 (m, 1H), 1.13–1.44 (m, 10H), 0.85 (m, 
1H).
The phosphorimdazolidate was dissolved in anhydrous DMF (0.5 mL). To this solution was 
added solid tributylammonium pyrophosphate (from Sigma, 36 mg, 0.0790 mmol) and 
tributylamine (30 µg, 161 µmol), successively. After the solution was stirred at room 
temperature for 3 days, 0.2 M trietylammonium bicarbonate (0.2 mL) was added, and the 
resulting mixture was lyophilized. The residue was purified by ion-exchange column 
chromatography using a Sephadex-DEAE A-25 resin with a linear gradient (0.01–1.0 M) of 
1.0 M ammonium bicarbonate as the mobile phase to give 5.7 mg of 5a (37.7%) as a white 
solid. 1H NMR (D2O): δ 8.01 (d, 1H, J = 8.0 Hz), 5.97 (d, 1H, J = 8.0 Hz), 4.75 (s, 1H), 4.72 
(d, 1H, J = 6.8 Hz), 4.54 (m, 1H), 3.99 (d, 1H, J = 6.7 Hz), 3.80 (m, 1H), 1.20–1.69 (m, 2H), 
0.95 (m, 1H). 31P NMR (D2O): δ −22.482, d (−10.914, −10.759), −8.979. MS (negative-ion 
FAB): 515 (MHNa−), 537 (MHNa2)−. High-resolution MS (negative-ion FAB) calcd for 
C11H16N2O14P3 [M2− + H+]−, 492.9814; found, 492.9832. HPLC: 1.737 min (99%) in 
solvent system A, 6.764 min (96%) in system B.
 Pharmacological Analyses
 PLC Activity
Agonist-promoted stimulation of inositol phosphate formation was measured at human 
P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11, receptors stably expressed in 1321N1 astrocytoma 
cells as previously described.32,33 Briefly, cells plated in 24 well dishes were labeled with 1 
µCi of [3H]myo-inositol/well (20 Ci/mmol; American Radiolabeled Chemicals, Inc., St. 
Louis, MO) in inositol-free Dulbecco’s modified Eagle’s medium (DMEM). [3H]-Inositol 
phosphate formation was quantitated the following day during a 10 min incubation at 37 °C 
in the presence of 10 mM LiCl. The EC50 values were averaged from 3 to 8 independently 
determined concentration-effect curves for each compound.
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P2Y1-receptor-promoted activation of PLC was studied in turkey erythrocyte membranes as 
we have described.8,34 Briefly, erythrocytes were incubated in inositol-free medium 
(DMEM; Gibco, Gaithersburg, MD) with 0.5 mCi of 2-[3H]myo-inositol (20 Ci/mmol; 
American Radiolabeled Chemicals, Inc., St. Louis, MO) for 18–24 h in a humidified 
atmosphere of 95% air/5% CO2 at 37 °C. Membranes were prepared and PLC activity was 
measured in 25 µL of [3H]inositol-labeled membranes (approximately 175 µg of protein, 
200–500 000 cpm/assay) in a medium containing 424 µM CaCl2, 0.91 mM MgSO4, 2 mM 
EGTA, 115 mM KCl, 5 mM KH2PO4, and 10 mM Hepes, pH 7.0. Assays (200 µL final 
volume) contained 1 µM GTPγS and the indicated concentrations of nucleotide analogues. 
Membranes were incubated at 30 °C for 5 min, and total [3H]inositol phosphates were 
quantified by anion-exchange chromatography as previously described.8,34
Agonist potencies were calculated using a four parameter logistic equation and the 
GraphPad software package (GraphPad, San Diego, CA). EC50 values (mean ± standard 
error (SE)) represent the concentration at which 50% of the maximal effect is achieved. 
Relative efficacies (%) were determined by comparison with the effect produced by a 
maximal effective concentration of full agonist in the same experiment. All concentration-
effect curves were repeated in at least three separate experiments carried out with different 
membrane preparations using duplicate or triplicate assays.
 Vacular Effects at the Rat Mesenteric Artery
UTP, UDP, NG-nitro-L-arginine methyl ester hydrochloride (L-NAME), α,β-methylene-ATP 
(α,β-meATP), and norepinephrine were purchased from Sigma. All substances were 
dissolved in saline 0.9%.
Vasodilatory responses to cumulatively added UTP and (N)-methanocarba-UTP, 5a, were 
examined in segments of the rat mesenteric artery using a myograph by methods previously 
described.18 Vessel segments were precontracted with 0.1 µM norepinephrine. The dilatory 
responses to both UTP and 5a were studied on the same vessel segment. The dilatory effects 
of (N) methanocarba-UDP, 6a, were not examined as there are no endothelial P2Y6 
receptors in the rat mesenteric artery.18
Vasocontractile responses of UDP, UTP, (N)-methanocarba-UDP, and (N)-methanocarba-
UTP were studied in the presence of 0.1 mM L-NAME to inhibit the effect of endothelial P2 
receptor-stimulated NO release. The antagonistic effect of (N)-methanocarba-UTP on UDP 
contraction was also assessed.
The negative logarithm of the drug concentration that elicited 50% dilation (pEC50) was 
determined by fitting the data to the Hill equation, using GraphPad Prism version 3.02. Rmax 
refers to maximum relaxation calculated as a percentage of the corresponding precontraction 
with 1 µM norepinephrine. In the contraction experiments, a plateau phase of the maximum 
contractile response was not reached within the agonist concentrations interval. Experiments 
were repeated on 2–7 vessel segments for each concentration of the substances. Statistical 
significance was accepted when P < 0.05, using Student’s t-test for paired data. Values are 
presented in the graphs as mean ± SEM.
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Effects of (N)-methanocarba or (S)-methanocarba modification of ATP on PLC activity in 
1321N1 astrocytoma cells expressing either hP2Y1 (A) or hP2Y2 (B) receptors. 
Concentration-dependent stimulation of inositol phosphate formation by adenine nucleotides 
(triphosphates), compounds 3a (▲), 3b (○), and 8a (▼). Membranes from [3H]inositol-
labeled membranes were incubated for 5 min at 30 °C in the presence of the indicated 
concentrations of agonist. The data shown are typical curves for at least three experiments 
carried out in duplicate using different membrane preparations.
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Effects of the (N)-methanocarba modification in uracil nucleotides (triphosphates) on 
activation of PLC in 1321N1 astrocytoma cells expressing either hP2Y2 (A) or hP2Y4 (B) 
receptors, showing concentration-dependent stimulation of inositol phosphate formation by 
compounds 5a (○) and 5b (●). Membranes from [3H]inositol-labeled membranes were 
incubated for 5 min at 30 °C in the presence of the indicated concentrations of agonist. The 
data shown are typical curves for at least three experiments carried out in duplicate using 
different membrane preparations.
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Effects of the (N)-methanocarba modification in uracil nucleotides (diphosphates) on 
activation of PLC in 1321N1 astrocytoma cells expressing hP2Y6 receptors, showing 
concentration-dependent stimulation of inositol phosphate formation by compound 6b (●) 
but not by compound 6a (○). Membranes from [3H]inositol-labeled membranes were 
incubated for 5 min at 30 °C in the presence of the indicated concentrations of nucleotide. 
The data shown are typical curves for at least three experiments carried out in duplicate 
using different membrane preparations.
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Vasodilatory responses to UTP (▲) and 5a (■) in the rat mesenteric artery. The uracil 
nucleotides were added after P2X receptor desensitization with 10 µM α,β-meATP. 
Relaxation is expressed as a percentage of an initial contraction induced by 1 µM 
norepinephrine. Data are shown as means ± sem of 5–7 vessel segments.
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Vasocontractile responses to uracil nucleotides UTP (▲) and 5a (■) in the rat mesenteric 
artery. The uracil nucleotides were added after P2X receptor desensitization with 10 µM α,β-
meATP. L-NAME (0.1 mM) was present to inhibit the release of NO. Data are shown as 
means ± sem of 2–4 vessel segments, except for the highest concentration of 5a, where n= 1.
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Vasocontractile responses to UDP (△), 6a (□), and UDP in the presence of 10 µM 6a (◇) in 
the rat mesenteric artery. The uracil nucleotides were added after P2X receptor 
desensitization with 10 µM α,β-meATP. L-NAME (0.1 mM) was present to inhibit the 
release of NO. Data are shown as means ± sem of 2–4 vessel segments.
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General Method for Stepwise Phosphorylation of (N)-Methanocarba Nucleosides: 
Formation of Di- and Triphosphates via the Phosphorimidazolidate Intermediate, IIa
a Reagents: (i) 1,1′-Carbonyldiimidazole, DMF, room temperature, 6 h and then 5% aqueous 
triethylamine, room temperature, 2 h. (ii) Tributylammonium phosphate, DMF, room 
temperature, 2 days, 43%. (iii) Tributylammonium pyrophosphate, DMF, 3 days, 6–40%.
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Synthesis of (N)-Methanocarba Adenosine 5′-Phosphate Derivativesa
a Reagents: (i) DEAD, Ph3P, THF (ref 40). (ii) NH3/i-PrOH, 95%. (iii) Palladium black, 
HCO2H, methanol, 76%. (iv) Di-t-butyl N,N-diethylphosphoramidite, tetrazole, THF, room 
temperature, 6 h and then m-CPBA, −78 °C, room temperature, 78%. (v) DOWEX 50 × 8–
200, methanol, 60–70 °C, 69%. (vi) (1) 1,1′Carbonyldiimidazole, (2) triethylamine/MeOH, 
(3) tributylammonium pyrophosphate, 20%.
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Synthesis of (N)-Methanocarba-uridine 5′-Monophosphate, 7a, and 5′-Di- and 
Triphosphates, 6a and 5aa
a Reagents: (i) (a) EtOCH=CHC(=O)NCO, benzene, room temperature, 10 min, 89%; (b) 2 
N H2SO4, MeOH, reflux, 30 min, 67%. (ii) Pd black, HCO2H, methanol, 74%. (iii) p-
Toluene sulfonic acid, acetone, room temperature, 4 h, 86%. (iv) Di-t-butyl N,N-
diethylphosphoramidite, tetrazole, THF, room temperature, 20 min and then m-CPBA, 
−78 °C, room temperature, 79%. (v) DOWEX 50 × 8–200, methanol, 60–70 °C, 86%. (vi) 
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(1) 1,1′-Carbonyldiimidazole, (2) triethylamine/MeOH, (3) tributylammonium phosphate or 
pyrophosphate, DMF, 2–3 days, 41% (6a), 38% (5a).
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Synthesis of (S)-Methanocarba Adenosine 5′-Phosphate Derivativesa
a Reagents: (i) POCl3, trimethyl phosphate, 60%. (ii) 1,1′-Carbonyldiimidazole, DMF, room 
temperature, 6 h and then 5% aqueous triethylamine, room temperature, 2 h. (iii) 
Tributylammonium pyrophosphate, DMF, 3 days, 30%.
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Table 1
Potencies for Methanocarba Analogues and the Corresponding Naturally Occurring Nucleotides in the 
Activation of Phospholipase C
Northern
a, methanocarba b, ribose
compd analogue subtype
EC50 (µM) of (N)-methanocarba
analoguea
EC50 (µM) of corresponding
ribose nucleotidea,b
3a ATP tP2Y1 0.014 ± 0.003 2.8 ± 0.7
hP2Y1 0.052 ± 0.022 1.5 ± 0.2
hP2Y2 0.091 ± 0.005 0.085 ± 0.012
hP2Y4 32% at 10 µM c
hP2Y11 34.5 ± 4.7% at 10 µM 17.25 ± 2.80
4a AMP tP2Y1 NEd NE
5a UTP hP2Y2 0.0159 ± 0.007 0.008 ± 0.002
hP2Y4 0.085 ± 0.005 0.049 ± 0.010
hP2Y6 NE
hP2Y11 NE
6a UDP hP2Y6 NE 0.015 ± 0.004
7a UMP hP2Y6 NE NE
Southern
compd analogue subtype
EC50 (µM) of (S)-methanocarba
analoguea
EC50 (µM) of corresponding
ribose nucleotidea,b
8a ATP tP2Y1 3.5 ± 0.66 2.8 ± 0.7
hP2Y1 7.2 ± 1.0 1.5 ± 0.2
hP2Y2 3.7 ± 0.5 0.085 ± 0.012
hP2Y4 NE c
hP2Y11 NE 17.25 ± 2.80








NE means “no effect at 100 µM”.
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